Rein Therapeutics

Rein Therapeutics(RNTX)

AUSTIN, TX
Biotechnology

Focus: Perpetually Active Peptides

Rein Therapeutics is a life sciences company focused on Perpetually Active Peptides.

NephrologyRespiratoryOncology
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0

Pipeline & Clinical Trials

Impact of the Routine Collection of Symptoms on Quality of Life in Dialysis Patients
Patients Reported Outcomes
N/A
Clinical Trials (1)
NCT05154708Impact of the Routine Collection of Symptoms on Quality of Life in Dialysis Patients
N/A
Daily hemodialysis at low dialysate flow
End Stage Renal Disease
N/A
Clinical Trials (1)
NCT01845012Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis
N/A
N/A
Clinical Trials (1)
NCT01114789Impact on the Proteolysis of Obesity in Dialysis
N/A
No systematic monitoring of symptoms
End Stage Renal Disease
N/A
Clinical Trials (1)
NCT06257134Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients.
N/A
Clinical Trials (1)
NCT06219798Evaluation of a Pathway on the Evolution of Renal Function in Patients With Advanced Chronic Kidney Disease
N/A
Caveolin-1-Scaffolding-Protein-Derived Peptide
Idiopathic Pulmonary Fibrosis
Phase 1
Clinical Trials (1)
NCT04233814Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
Phase 1
Clinical Trials (1)
NCT05954988A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
Phase 1
Phase 2
Clinical Trials (1)
NCT04159831A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
Phase 2
Clinical Trials (1)
NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Phase 2
Phase 3
Clinical Trials (1)
NCT06364631CARE1 Pragmatic Clinical Trial
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 10 clinical trials
SEC Filings: 2 available

Financials (FY2024)

Revenue
$0
R&D Spend
$4M78%
Net Income
-$16M
Cash
$17M